Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Matosinhos

691 clinical trials in Matosinhos, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Matosinhos at a glance
691
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

691 trials in Matosinhos

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Vaccines US Inc.

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Matosinhos

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on Frontotemporal Dementia and various forms of Multiple Sclerosis, including primary progressive and secondary progressive variants. Studies are evaluating novel therapeutic approaches and long-term treatment options.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Epilepsy Interventions

Clinical investigations include assessment of new compounds for refractory focal onset epilepsy and progressive neurological conditions.

02 Respiratory Medicine

Comprehensive studies addressing Pulmonary Fibrosis and chronic respiratory conditions. Research focuses on innovative treatments for chronic rhinosinusitis and progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis
  • Chronic Rhinosinusitis
  • COPD Management

Trials aim to improve lung function and reduce disease progression in various respiratory conditions.

03 Cardiovascular Studies

Advanced research in Heart Failure and stroke prevention, particularly focusing on patients with atrial fibrillation. Studies evaluate new treatment combinations and preventive strategies.

  • Stroke Prevention
  • Heart Failure Management
  • Systemic Embolism Prevention

Research includes comparative studies of new medications for cardiac conditions and prevention strategies.

04 Oncology Research

Targeted studies on Neuroendocrine Cancers, including small cell lung cancer and other specialized cancer types. Research focuses on advanced treatment options for patients with limited therapeutic alternatives.

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
  • Advanced Cancer Therapies

Trials evaluate new therapeutic approaches for patients who have progressed after standard treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.